Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC, Hochgräfe F, Wu J, Millar EK, Barraclough J, Stone A, McCloy RA, Lee CS, Roberts C, Ali NA, Boulghourjian A, Schmich F, Linding R, Farrow L, Gee JM, Nicholson RI, O'Toole SA, Sutherland RL, Musgrove EA, Butt AJ, Daly RJ. Browne BC, et al. Among authors: musgrove ea. FEBS J. 2013 Nov;280(21):5237-57. doi: 10.1111/febs.12441. Epub 2013 Aug 19. FEBS J. 2013. PMID: 23876235 Free article.
c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM, Sergio CM, Anderson LR, Inman CK, Eggleton SA, Murphy NC, Millar EK, Crea P, Kench JG, Alles MC, Gardiner-Garden M, Ormandy CJ, Butt AJ, Henshall SM, Musgrove EA, Sutherland RL. McNeil CM, et al. Among authors: musgrove ea. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):147-55. doi: 10.1016/j.jsbmb.2006.09.028. Epub 2006 Oct 18. J Steroid Biochem Mol Biol. 2006. PMID: 17052904
Cyclin D as a therapeutic target in cancer.
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Musgrove EA, et al. Nat Rev Cancer. 2011 Jul 7;11(8):558-72. doi: 10.1038/nrc3090. Nat Rev Cancer. 2011. PMID: 21734724 Review.
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Caldon CE, et al. Among authors: musgrove ea. Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7. Mol Cancer Ther. 2012. PMID: 22564725
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer.
Stone A, Cowley MJ, Valdes-Mora F, McCloy RA, Sergio CM, Gallego-Ortega D, Caldon CE, Ormandy CJ, Biankin AV, Gee JM, Nicholson RI, Print CG, Clark SJ, Musgrove EA. Stone A, et al. Among authors: musgrove ea. Mol Cancer Ther. 2013 Sep;12(9):1874-85. doi: 10.1158/1535-7163.MCT-13-0012. Epub 2013 Jul 16. Mol Cancer Ther. 2013. PMID: 23861345
198 results